HopeStage
Back to all studies
CompletedNCT06653296

ENX-102 dose and safety study for generalized anxiety

About this titleRead the official source — NCT06653296

Researchers compared ENX-102 and placebo, tracking side effects to assess safety and tolerability in people with an anxiety condition.

Medication studyAges 18–65United Kingdom
The study in practice

Understand this study

What did researchers investigate?

Researchers compared ENX-102 and placebo, tracking side effects to assess safety and tolerability in people with an anxiety condition.

Who was this study for?

This study was for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Liverpool and 2 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: December 9, 2024
Recruitment status
Completed
Enrollment listed in the registry
38
Sponsor
Engrail Therapeutics INC
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United Kingdom
Age range
From 18 Years to 65 Years
Official registry ID
NCT06653296
Official title
Show the full official title

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of ENX-102 and Determine a Dose-response for ENX-102 in Patients With Generalized Anxiety Disorder (GAD)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Liverpool · Blackpool · Manchester

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared ENX-102 and placebo, tracking side effects to assess safety and tolerability in people with an anxiety condition.

Who is behind this study?

The study sponsor is Engrail Therapeutics INC.

Did this study involve medication?

Yes. The study involved medication, including ENX-102 and Placebo.

Who was this study for?

This study was for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies